(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 8.57% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Ani Pharmaceuticals's revenue in 2025 is $826,880,000.On average, 10 Wall Street analysts forecast ANIP's revenue for 2025 to be $19,796,340,644, with the lowest ANIP revenue forecast at $18,408,428,537, and the highest ANIP revenue forecast at $20,724,536,356. On average, 10 Wall Street analysts forecast ANIP's revenue for 2026 to be $21,708,679,957, with the lowest ANIP revenue forecast at $20,103,941,692, and the highest ANIP revenue forecast at $23,749,766,824.
In 2027, ANIP is forecast to generate $23,817,173,920 in revenue, with the lowest revenue forecast at $21,163,131,860 and the highest revenue forecast at $27,142,590,656.